Prosight Management’s BridgeBio Pharma BBIO Stock Holding History

Prosight Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,000	Closed	-$2.29M	–	48
2025 Q4	$2.29M	Sell	30,000 -234,500	-89%	-$15.4M	0.47%	32
2025 Q3	$13.7M	Sell	264,500 -208,187	-44%	-$10.2M	3.2%	10
2025 Q2	$20.4M	Sell	472,687 -137,313	-23%	-$4.99M	4.98%	5
2025 Q1	$21.1M	Sell	610,000 -385,000	-39%	-$13M	6.93%	3
2024 Q4	$27.3M	Sell	995,000 -91,810	-8%	-$2.37M	7.55%	3
2024 Q3	$27.7M	Buy	1,086,810 +286,810	+36%	+$7.53M	6.81%	3
2024 Q2	$20.3M	Buy	800,000 +210,470	+36%	+$5.75M	6.06%	4
2024 Q1	$18.2M	Buy	+589,530	New	+$20M	5.07%	7
2023 Q2	–	Sell	-13,000	Closed	-$216K	–	39
2023 Q1	$216K	Sell	13,000 -76,027	-85%	-$887K	0.1%	38
2022 Q4	$678K	Buy	+89,027	New	+$852K	0.37%	34

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prosight Management's BBIO Position: Q1 2026 in Review

Prosight Management sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 30,000 shares — an estimated $2.29M sold.

Prosight Management first reported a position in BBIO in Q4 2022 and held it in 10 quarters. The position peaked at $27.7M in Q3 2024. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Prosight Management reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
Prosight Management sold 30,000 BridgeBio Pharma shares in Q1 2026, an estimated $2.29M.
Prosight Management first reported a position in BridgeBio Pharma in Q4 2022 and held it in 10 quarters.
Prosight Management's BridgeBio Pharma position peaked at $27.7M in Q3 2024.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.